Pharma/Biotech manufacturers still struggle to exploit the full potential of digitalization
India Director, Life Sciences, Dassault Systemes, Bengaluru
Across life sciences, the need for digitalisation has prevailed for years in India, despite being the second largest contributor of global biotech and pharmaceutical workforce. While we’re seeing progress in adoption of digital technologies for business and manufacturing processes in the pharmaceutical and biotech industries, manufacturers still struggle to exploit the full potential of digitalisation.
From an ongoing trend perspective - Digital Transformation, fueled by new age innovations like Artificial Intelligence (AI) and 3D Printing can lead technology adoption in the sector. AI can facilitate repurposing of drugs, faster drug development, patient identification, better and insights from clinical trials data, predict the spread of the disease etc. AI has been used to identify and screen existing drugs that could be repurposed to treat COVID-19, aid clinical trials, analyse trial data and patient electronic medical records (EMRs). Similarly, 3D Printing of body parts are used in facial surgeries, limb surgeries and others.
With the advancement of conventional and disruptive technologies, the healthcare and life sciences sector in India is transforming, characterised by data mining, clinical diagnoses, and self-monitoring devices to help maintain a healthy lifestyle. Unearthing the current state of adoption of disruptive technologies across the life sciences sector in India, technology will play a huge role in the impact and scope of embracing technology for healthcare transformation. It will enable the entire ecosystem to take strategic decisions and resolve technology adoption concerns and challenges.
Additionally, while life sciences companies have access to abundant data, it is a challenge to find an authentic source that provides accurate data.